Obermatt
See Similar Stocks →

Corbus Pharmaceuticals Holdings

NAQ:CRBP · US21833P3010
BiotechnologySmall

360° View

62
Price/Sales5
Price/Earnings48
Price/Book42
Dividend Yield1
Revenue Growth—
Profit Growth19
Capital Growth100
TSR 52w32
Leverage89
Liquidity61
Refinancing8
Combined40
Analyst Opinions91
Pro Holdings45
Opinion Changes14
Market Pulse91

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded2009
Employees46
Websitecorbuspharma.com
ISINUS21833P3010
Last UpdateApr 2, 2026
Index & Theme
OncologyObesityBiotechnologyClinical TrialsPharmaceutical

Description

Corbus Pharmaceuticals Holdings, Inc. operates as an oncology and obesity company. The company is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. The company’s p…

Analysis

Corbus Pharmaceuticals Holdings's 360° View rank of 62 places it above its peer average — better than 62% of its true peers.

It's growing solidly (62) and expensive versus peers (12). On safety it is financially sound (59), and the market shows strongly positive sentiment (81). Taken together, its Combined rank of 40 reads as below its peer average.

360° rank · history

1007550250
62
2026

All-time high

62

Jun 2026

All-time low

44

Mar 2026

Average rank

53

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
5
—
—
—
Price/Earnings
48
—
—
—
Price/Book
42
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
12
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Corbus Pharmaceuticals Holdings with its peers
Karyopharm Therapeutics
NSQ:KPTI
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kura Oncology
NSQ:KURA
30
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Karman Holdings
NYQ:KRMN
6
CountryUSA
IndustryAerospace & Defense
SizeMedium
Full Stock Analysis →
Xeris Pharmaceuticals
NSQ:XERS
70
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
LifeVantage
NAQ:LFVN
33
CountryUSA
IndustryPersonal Products
SizeSmall
Full Stock Analysis →
Myriad Genetics
NSQ:MYGN
12
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →